Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy
European Journal of Neurology Dec 08, 2017
Olberg HK, et al. - The authors performed this study to examine the influence of immunomodulatory therapies on the antibody response and seroprotection rates in multiple sclerosis (MS) patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls. They proposed that in cases of insufficient protection, MS patients receiving fingolimod or natalizumab ought to be considered for a second dose of the vaccine. The outcomes further showed that new immunomodulatory treatment regimens needed to be systematically assessed for their influence on influenza-specific vaccine responses.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins